Wed, March 1, 2023
Tue, February 28, 2023
Mon, February 27, 2023

Neena Bitritto-Garg Maintained (ACAD) at Hold and Held Target at $19 on, Feb 28th, 2023


  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. hold-and-held-target-at-19-on-feb-28th-2023.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication

Neena Bitritto-Garg of Citigroup, Maintained "ACADIA Pharmaceuticals Inc." (ACAD) at Hold and Held Target at $19 on, Feb 28th, 2023.

Neena has made no other calls on ACAD in the last 4 months.



There are 5 other peers that have a rating on ACAD. Out of the 5 peers that are also analyzing ACAD, 3 agree with Neena's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Jay Olson of "Oppenheimer" Maintained at Hold with Increased Target to $17 on, Wednesday, February 15th, 2023
  • Tessa Romero of "JP Morgan" Maintained at Hold with Decreased Target to $17 on, Monday, November 14th, 2022
  • Esther Hong of "Loop Capital" Initiated at Hold and Held Target at $17 on, Tuesday, November 1st, 2022


These are the ratings of the 2 analyists that currently disagree with Neena


  • Yatin Suneja of "Guggenheim" Upgraded from Hold to Strong Buy and Held Target at $22 on, Tuesday, January 3rd, 2023
  • Salveen Richter of "Goldman Sachs" Downgraded from Hold to Strong Sell and Decreased Target to $12 on, Friday, November 4th, 2022

Publication Contributing Sources